Xolair, already used to treat asthma, has been shown to be effective in preventing food allergic reactions. In the United States, the FDA has authorized its specific use in adults and children over one year of age.
With this treatment, allergy patients experienced a significant increase in their tolerance to foods such as peanuts, tree nuts, eggs, milk and wheat. This molecule, also known as omalizumab, blocks the action of antibodies responsible for allergic reactions. However, it does not allow the resumption of allergen consumption, but aims to reduce reactions in the event of accidental ingestion.
This progress is crucial in a context where food allergies are of increasing concern in the United States.
 Pascal Lemontel
|
27/02/2024 | 
